Semaglutide (Ozempic/Wegovy) for Weight Loss in Bangalore

What is Semaglutide?

Semaglutide is a GLP-1 (Glucagon-Like Peptide-1) receptor agonist that was originally developed for the management of type 2 diabetes. During clinical trials, researchers observed that patients using Semaglutide experienced significant weight loss as a secondary benefit. This discovery led to the development of higher-dose formulations specifically approved for weight management. Compare all GLP-1 medications →

Semaglutide is available in two primary formulations: Ozempic (approved for diabetes management with a maximum dose of 1.0 mg weekly) and Wegovy (approved for weight management with a maximum dose of 2.4 mg weekly). Both contain the same active ingredient, but Wegovy is formulated at higher doses specifically calibrated for maximum weight loss efficacy. At EQUA, our endocrinologists determine which formulation and dosing protocol is right for each patient based on their medical history, metabolic profile, and weight loss goals.

Semaglutide has been extensively studied in landmark clinical trials including the STEP (Semaglutide Treatment Effect in People with obesity) program, which involved over 4,500 participants across multiple countries. The results demonstrated that Semaglutide at the 2.4 mg weekly dose produced an average weight loss of 14.9% of initial body weight over 68 weeks, far exceeding the results achieved with lifestyle modification alone.

How Semaglutide Works for Weight Loss

Semaglutide produces weight loss through several complementary mechanisms that work together to create a powerful and sustained effect:

• Appetite Suppression: Semaglutide activates GLP-1 receptors in the hypothalamus, the part of the brain that regulates appetite. This significantly reduces hunger signals and food cravings, making it easier to eat less without feeling deprived.
• Delayed Gastric Emptying: By slowing how quickly food moves from the stomach to the small intestine, Semaglutide prolongs the feeling of fullness after meals. Patients report feeling satisfied with smaller portions and for longer periods after eating.
• Improved Insulin Sensitivity: Semaglutide enhances the body's response to insulin, which helps reduce the fat-storage signals that contribute to weight gain, particularly around the abdominal area.
• Reduced Food Reward: GLP-1 receptors in the brain's reward centers are activated by Semaglutide, which reduces the pleasurable response to high-calorie, sugary, and fatty foods. This naturally decreases cravings and makes it easier to make healthier food choices.

This multi-targeted approach is what makes Semaglutide significantly more effective than earlier weight loss medications, which typically worked through a single mechanism. The combination of reduced appetite, enhanced satiety, improved metabolism, and reduced food cravings creates a comprehensive solution that addresses the complex biology of obesity.

Semaglutide therapy follows a gradual dose escalation protocol to minimize side effects and allow your body to adjust to the medication. The typical dosing schedule for weight loss (Wegovy) is:

• Weeks 1-4: 0.25 mg once weekly (starting dose)
• Weeks 5-8: 0.5 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onwards: 2.4 mg once weekly (target maintenance dose)

Each dose escalation is guided by your endocrinologist based on your tolerance and response. Some patients may require a slower titration schedule if they experience side effects. The target dose of 2.4 mg weekly is the dose at which maximum weight loss efficacy is achieved, though many patients begin to see meaningful weight loss from the 1.0 mg dose onwards.

The cost of Semaglutide injections in Bangalore varies depending on the brand (Ozempic vs Wegovy), the prescribed dose, and the duration of treatment. Estimated monthly costs are:

• Starting doses (0.25-0.5 mg weekly): Rs. 8,000 - Rs. 12,000 per month
• Intermediate doses (1.0-1.7 mg weekly): Rs. 12,000 - Rs. 18,000 per month
• Target dose (2.4 mg weekly - Wegovy): Rs. 18,000 - Rs. 22,000 per month

At EQUA, we provide transparent pricing and discuss all costs during your initial consultation. The consultation fee includes a comprehensive evaluation, personalized treatment plan, and ongoing monitoring by our endocrinologists. Many patients find that the cost of Semaglutide is offset by reduced healthcare expenses related to obesity-associated conditions like diabetes, hypertension, and joint problems.

It is important to note that Semaglutide requires a valid prescription and should only be obtained from licensed pharmacies. Avoid purchasing from unverified online sources, as counterfeit products pose serious health risks.

Semaglutide is an FDA-approved and DCGI-approved medication with an extensive safety profile established through clinical trials involving tens of thousands of patients. Common side effects are typically mild and temporary, especially when the dose is escalated gradually:

• Nausea: The most common side effect, affecting approximately 40% of patients during the initial weeks. It typically resolves within 2-4 weeks as the body adjusts.
• Vomiting and Diarrhea: Less common than nausea, these gastrointestinal effects are usually transient and mild.
• Constipation: Some patients experience constipation, which can be managed with increased water intake and dietary fiber.
• Injection Site Reactions: Mild redness, swelling, or discomfort at the injection site can occur but typically resolves quickly.

Serious side effects are rare but require awareness. These include pancreatitis (inflammation of the pancreas), gallbladder disease (including gallstones), and severe gastrointestinal events. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Our endocrinologists perform a thorough evaluation of your medical history to ensure Semaglutide is safe for you before prescribing.

Am I Eligible for Semaglutide?

Semaglutide for weight management is prescribed for adults who meet these criteria:

• BMI ≥ 30 (obese range), OR
• BMI 27–29.9 (overweight) with at least one weight-related condition: Type 2 Diabetes, PCOS, hypertension, high cholesterol, sleep apnoea, or fatty liver disease
• BMI ≥ 25 for Indian patients — lower thresholds apply due to higher metabolic risk in South Asian populations

Your assessment at EQUA includes body composition analysis, metabolic blood panels (HbA1c, lipid profile, liver function), blood pressure, waist circumference, and medical history review. Semaglutide is not suitable if you have a personal/family history of medullary thyroid carcinoma, MEN-2 syndrome, are pregnant/breastfeeding, or have a history of pancreatitis.

Take our free obesity risk assessment →

Drug Interactions & Precautions

• Insulin & sulfonylureas: May need dose reduction to avoid hypoglycaemia.
• Oral contraceptives: Delayed stomach emptying may reduce absorption. Consider alternative contraception.
• Warfarin/DOACs: May require closer INR monitoring.
• Pregnancy: Discontinue at least 2 months before planned pregnancy. Not recommended during breastfeeding.

How to Inject Semaglutide

Semaglutide comes as a pre-filled pen (Wegovy or Ozempic). Our nursing team demonstrates the technique:

• Sites: Abdomen (2 inches from navel), thigh, or upper arm. Rotate weekly.
• Technique: Clean with alcohol swab, pinch skin, insert needle at 90°, press button, hold 10 seconds.
• Timing: Same day each week, with or without food.
• Missed dose: Take within 48 hours. If more than 48 hours, skip and resume schedule. Do not double-dose.
• Storage: Refrigerate unopened pens (2–8°C). Once opened, room temperature (<30°C) for up to 28 days.

What Happens When You Stop Semaglutide?

Weight regain is common after stopping. Studies show 50–80% of lost weight may return within 1–5 years due to persistent hormonal adaptations. Semaglutide is generally prescribed as a long-term treatment. At EQUA, we combine medication with lifestyle modifications and offer gradual dose reduction protocols when appropriate.

Learn why obesity is a chronic disease →

Semaglutide FAQs